Opinion|Videos|January 6, 2025
The Promise of Emerging IgAN Therapies
Key Takeaways
- Biomarkers, including genetic mutations and protein expressions, are vital for predicting disease progression and treatment response.
- Advanced diagnostic techniques are essential for identifying molecular and cellular indicators that inform patient prognosis.
Panelists discuss how emerging therapies are expected to address the unmet need for treatments that not only reduce proteinuria but also target the underlying immune dysfunction associated with IgA nephropathy.
Advertisement
Episodes in this series
- How do you believe emerging therapies will address the unmet need for treatments that reduce proteinuria while also modifying the disease’s underlying immune dysfunction?
- What are the most promising mechanisms of action being explored in these new therapies?
Advertisement
Related to this article
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
Advertisement
Advertisement
Trending on HCPLive
1
Phase 3 PARADIGM: HLP003 (Psilocibin-d10) for Adjunctive MDD Use
2
Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD
3
Weekly Insulin Efsitora Alfa (Onswik) Gains FDA approval for Type 2 Diabetes
4
Why Clinicians Should Not Wait to Augment Inadequate Response in MDD
5